Russell Cohen to Drug Substitution
This is a "connection" page, showing publications Russell Cohen has written about Drug Substitution.
Connection Strength
0.207
-
Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
Score: 0.151
-
Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review. Adv Ther. 2025 Mar; 42(3):1360-1392.
Score: 0.056